GAP Supply Act
Summary
The GAP Supply Act (HR7528) is an early-stage procedural bill with no funding authorization. It extends a regulatory timeline for compounding facilities during drug shortages but has near-zero near-term market impact. Current real market data shows $VTRS at $15.04 within its 52-week range of $8.19–$16.47, with a +11.32% 30-day gain reflecting broader market trends, not this bill.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7528 is an early-stage procedural bill with zero funding — no direct market impact.
- 2.Primary effect is regulatory relief for compounding pharmacies (mostly private companies), not public company earnings.
- 3.$VTRS's 11.32% 30-day gain to $15.04 is unrelated to this bill; driven by broader market dynamics.
- 4.No actionable trade signal. Monitor committee markup for any amendments that add funding or expand scope.
Market Implications
No actionable market implications from HR7528 in its current state. at $15.04 within range $8.19–$16.47 shows no bill-specific catalyst. Investors should ignore this bill unless it receives a committee markup date, which would signal minimal advancement. For generic injectable exposure, $VTRS's recent 30-day trend (+11.32%) suggests broader momentum that may continue independent of legislative noise.
Full Analysis
- What happened and status: HR7528 was introduced by Rep. Carter (R-GA) on February 12, 2026, and referred to the House Energy and Commerce Committee. It has not moved beyond this single referral. The bill amends Section 503B of the FD&C Act to change a timing requirement for outsourcing facilities — giving them 180 calendar days (instead of 'at the time') to continue supplying a drug after it is placed on the FDA shortage list. This is a purely procedural regulatory change. No funds are authorized or appropriated. 2) The money trail: $0. This bill contains no spending authorization, no tax credits, no grants, and no procurement directives. It modifies FDA regulatory compliance timelines only. The mechanism is a reduction in legal risk for compounding pharmacies, not a market-enlarging subsidy. 3) Structural winners and losers: The primary beneficiaries are small-to-mid-sized 503B outsourcing facilities (mostly private companies, not publicly traded). Viatris and other generic injectable manufacturers face marginally increased competition from more authorized compounding during shortages, but the effect is too small and indirect to materially alter earnings. No public pure-play compounding pharmacy tickers exist on US exchanges. 4) Real market data context: is trading at $15.04, up +3.08% over 7 days and +11.32% over 30 days. The stock is near the top of its 52-week range ($8.19–$16.47), but this move is attributable to broader sector rotation and company-specific factors (e.g., patent settlements, generic drug pricing cycles), not this bill. 5) Timeline: The bill is at the earliest possible stage. To become law, it must pass committee markup, pass the House floor, pass the Senate (no companion bill exists), and be signed by the President. Given the 119th Congress is in its second session (2026 is an election year), the window for advancing non-urgent regulatory bills is narrow. Passage probability is low.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →